Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology

Abstract

Regenerative medicine holds great promise as a way of addressing the limitations of current treatments of ischaemic disease. In preclinical models, transplantation of different types of stem cells or progenitor cells results in improved recovery from ischaemia. Furthermore, experimental studies indicate that cell therapy influences a spectrum of processes, including neovascularization and cardiomyogenesis as well as inflammation, apoptosis and interstitial fibrosis. Thus, distinct strategies might be required for specific regenerative needs. Nonetheless, clinical studies have so far investigated a relatively small number of options, focusing mainly on the use of bone marrow-derived cells. Rapid clinical translation resulted in a number of small clinical trials that do not have sufficient power to address the therapeutic potential of the new approach. Moreover, full exploitation has been hindered so far by the absence of a solid theoretical framework and inadequate development plans. This article reviews the current knowledge on cell therapy and proposes a model theory for interpretation of experimental and clinical outcomes from a pharmacological perspective. Eventually, with an increased association between cell therapy and traditional pharmacotherapy, we will soon need to adopt a unified theory for understanding how the two practices additively interact for a patient's benefit. LINKED ARTICLESThis article is part of a themed section on Regenerative Medicine and Pharmacology: A Look to the Future. To view the other articles in this section visit http://dx

Role of vascular endothelial growth factor in inducing production of angiopoetin-1 – in vivo study in Fisher rats

“…HGF inhibits vascular permeability and pro-inflammatory effects [19,20]. Bicistronic plasmids coding VEGF with HGF seems to be effective during the first stage of the neoangiogenesis gene therapy [21,22].…”

Heart-on-a-chip based on stem cell biology

“…The difficulty in regenerating damaged myocardial tissue has led to explore the application of stem cells therapy. A number of stem cell types have been investigated as possible sources for regenerating damaged myocardium: resident cardiac stem cells (CSC), embryonic stem cells (ESC), induced pluripotent stem cells (iPSC), adult bone marrow-derived (BM) cells, mesenchymal cells, endothelial progenitor cells umbilical cord blood (UCB) cells (Laflamme and Murry, 2011, Kumar et al, 2010, Segers and Lee, 2008, Shah and Shali, 2009, Kucia et al, 2004Jadczyk et al, 2013, Jameel and Zhang, 2010. CSCs are naturally residing within the myocardium.…”

Transplantation of Allogeneic Pericytes Improves Myocardial Vascularization and Reduces Interstitial Fibrosis in a Swine Model of Reperfused Acute Myocardial Infarction

“…Transplantation of proangiogenic cells following an acute myocardial infarction (MI) may help prevent the infarct extension by promoting cardiomyocyte rescue, awakening the hibernated myocardium in the area at risk, and modulating inflammation and fibrosis 2, 3. Cell therapy of coronary artery disease has evolved rapidly from bench to bedside; however, despite positive results in murine models of MI, small‐ or medium‐sized clinical studies and meta‐analyses have only shown modest benefit in humans 4, 5, 6, 7.…”